MedElevator
Войти в исследования Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
Аннотация
Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer chemotherapy. We used decision analysis to compare the cost-effectiveness of rHuEPO supplemented with red blood cell (RBC) transfusions with conventional treatment with RBC transfusions alone. At baseline, we analysed the use of rHuEPO as secondary prophylaxis according to effectiveness estimates from a community-based oncology study. In order to reduce the probability of transfusions from 21.9% to 10.4%, and the number of RBC units per patient per month from 0.55 to 0.29, 150 units kg(-1) s.c. rHuEPO three times per week for 4 months resulted in an incremental cost of $189,652 per quality-adjusted life year (QALY). In patients treated with cisplatin-containing chemotherapy, rHuEPO added $190,142 per QALY. In a hypothetical scenario of a transfusion pattern that maintained the same haemoglobin level of rHuEPO-responsive patients, the marginal cost of rHuEPO was always greater than $100,000 per QALY. Results were stable with regard to variations in the probability of blood-borne infections, quality of life of responding patients and cancer-related mortality. The additional cost could be lowered to less than $100,000 per QALY by saving 4.5 RBC units over 4 months for any patient treated. In conclusion, according to current use, rHuEPO is not cost-effective in the treatment of chemotherapy-induced anaemia. More tailored utilization of the drug and better consideration of predictive response indicators may lead to an effective, blood-sparing alternative.
Перевод полного текста: Перевод в очереди
Полный текст источника
https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .
Abels R. I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. 87 Suppl 1 1992 4 11 Acta Haematol 1574966 10.1159/000204780
Abels R. Erythropoietin for anaemia in cancer patients. 29A Suppl 2 1993 S2 S8 Eur J Cancer 8398361 10.1016/s0959-8049(05)80281-3
Birkmeyer J. D. Goodnough L. T. AuBuchon J. P. Noordsij P. G. Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. 33 7 7 1993 544 551 Transfusion 8333017 10.1046/j.1537-2995.1993.33793325048.x
Blajchman M. A. Bull S. B. Feinman S. V. Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group. 345 8941 7 1 1995 21 25 Lancet 7528310 10.1016/s0140-6736(95)91153-7
Cascinu S. Fedeli A. Del Ferro E. Luzi Fedeli S. Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. 12 5 5 1994 1058 1062 J Clin Oncol 8164030 10.1200/JCO.1994.12.5.1058
Cazzola M. Messinger D. Battistel V. Bron D. Cimino R. Enller-Ziegler L. Essers U. Greil R. Grossi A. Jäger G. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. 86 12 15 12 1995 4446 4453 Blood 8541533
Del Mastro L. Garrone O. Sertoli M. R. Canavese G. Catturich A. Guenzi M. Rosso R. Venturini M. A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. 30A 5 1994 606 610 Eur J Cancer 7521652 10.1016/0959-8049(94)90529-0
Del Mastro L. Venturini M. Lionetto R. Garrone O. Melioli G. Pasquetti W. Sertoli M. R. Bertelli G. Canavese G. Costantini M. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. 15 7 7 1997 2715 2721 J Clin Oncol 9215845 10.1200/JCO.1997.15.7.2715
Dodd R. Y. The risk of transfusion-transmitted infection. 327 6 6 8 1992 419 421 N Engl J Med 1625717 10.1056/NEJM199208063270610
Donahue J. G. Muñoz A. Ness P. M. Brown D. E. Jr Yawn D. H. McAllister H. A. Jr Reitz B. A. Nelson K. E. The declining risk of post-transfusion hepatitis C virus infection. 327 6 6 8 1992 369 373 N Engl J Med 1320736 10.1056/NEJM199208063270601
Etchason J. Petz L. Keeler E. Calhoun L. Kleinman S. Snider C. Fink A. Brook R. The cost effectiveness of preoperative autologous blood donations. 332 11 16 3 1995 719 724 N Engl J Med 7854380 10.1056/NEJM199503163321106
Garton J. P. Gertz M. A. Witzig T. E. Greipp P. R. Lust J. A. Schroeder G. Kyle R. A. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. 155 19 23 10 1995 2069 2074 Arch Intern Med 7575066
Glaspy J. Bukowski R. Steinberg D. Taylor C. Tchekmedyian S. Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. 15 3 3 1997 1218 1234 J Clin Oncol 9060566 10.1200/JCO.1997.15.3.1218
Henry D. H. Abels R. I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. 21 2 Suppl 3 4 1994 21 28 Semin Oncol 8202722
Koretz R. L. Abbey H. Coleman E. Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. 119 2 15 7 1993 110 115 Ann Intern Med 8512159 10.7326/0003-4819-119-2-199307150-00003
Koretz R. L. Stone O. Mousa M. Gitnick G. L. Non-A, non-B posttransfusion hepatitis--a decade later. 88 5 Pt 1 5 1985 1251 1254 Gastroenterology 3920112 10.1016/s0016-5085(85)80087-1
Lackritz E. M. Satten G. A. Aberle-Grasse J. Dodd R. Y. Raimondi V. P. Janssen R. S. Lewis W. F. Notari E. P. 4th Petersen L. R. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. 333 26 28 12 1995 1721 1725 N Engl J Med 7491134 10.1056/NEJM199512283332601
Leese B. Hutton J. Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. 1 5 5 1992 346 356 Pharmacoeconomics 10146999 10.2165/00019053-199201050-00006
Ludwig H. Fritz E. Leitgeb C. Pecherstorfer M. Samonigg H. Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. 84 4 15 8 1994 1056 1063 Blood 7741835
Mohandas K. Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. 35 5 5 1995 427 430 Transfusion 7740615 10.1046/j.1537-2995.1995.35595259154.x
Schreiber G. B. Busch M. P. Kleinman S. H. Korelitz J. J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. 334 26 27 6 1996 1685 1690 N Engl J Med 8637512 10.1056/NEJM199606273342601
Seeff L. B. Buskell-Bales Z. Wright E. C. Durako S. J. Alter H. J. Iber F. L. Hollinger F. B. Gitnick G. Knodell R. G. Perrillo R. P. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. 327 27 31 12 1992 1906 1911 N Engl J Med 1454085 10.1056/NEJM199212313272703
Sheffield R. Sullivan S. D. Saltiel E. Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. 31 1 1 1997 15 22 Ann Pharmacother 8997459 10.1177/106002809703100101
Sheingold S. Churchill D. Muirhead N. Laupacis A. Labelle R. Goeree R. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. 34 9 5 1992 983 991 Soc Sci Med 1631611 10.1016/0277-9536(92)90129-e
Tong M. J. el-Farra N. S. Reikes A. R. Co R. L. Clinical outcomes after transfusion-associated hepatitis C. 332 22 1 6 1995 1463 1466 N Engl J Med 7739682 10.1056/NEJM199506013322202
Tretiak R. Laupacis A. Rivière M. McKerracher K. Souêtre E. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. 154 10 15 5 1996 1501 1508 CMAJ PMC1487839 8625000
Wong J. B. Koff R. S. Tinè F. Pauker S. G. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. 122 9 1 5 1995 664 675 Ann Intern Med 7702228 10.7326/0003-4819-122-9-199505010-00004
Wurnig C. Windhager R. Schwameis E. Kotz R. Zoubek A. Stockenhuber F. Kurz R. W. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). 36 2 2 1996 155 159 Transfusion 8614967 10.1046/j.1537-2995.1996.36296181929.x
de Campos E. Radford J. Steward W. Milroy R. Dougal M. Swindell R. Testa N. Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. 13 7 7 1995 1623 1631 J Clin Oncol 7602351 10.1200/JCO.1995.13.7.1623
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.